Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 4, 2023 4:05 PM EDTMultiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza
Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company through next phase of growth
 $2.3 billion in cash, cash equivalents, and investments as of March 31, 2023Â
SAN FRANCISCO, May 04, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.
Vir is at an exciting inflection... More
